A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

NCT03516071 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Brivanib 800 mg, QD
DRUG: Brivanib 400 mg, BID

Sponsor

Zai Lab (Shanghai) Co., Ltd.